muc-1 prr patent, page-6

Yes professor, and a very good point.

This is what Antisoma stays about AS1402, 'Preclinical experiments showed that AS1402 can act as a 'marker flag', attaching itself to tumour cells and helping components of the patient’s immune system to find and destroy them.

huHMFG1 binds specifically to MUC1, a cell membrane glycoprotein that is overexpressed in a variety of tumours, including breast, ovarian, pancreatic, gastric and colon cancers. In laboratory experiments, huHMFG1 was shown to be a potent inducer of antibody-dependent cellular cytotoxicity (ADCC)'.

and another sites explains monoclonal antibody HuHMFG1 as, 'A humanized monoclonal antibody directed against MUC1, a mucin glycoprotein overexpressed in breast and other carcinomas. Monoclonal antibody HuHMFG1 stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing MUC1, resulting in a decrease in tumor burden'.

The difference between Cvac and AS1402 may be the Mannan Fusion process, which assists the bodies ammune system in identifying and destroying the cancer. This 'delivery method' could be the difference in the success Prima have had with Cvac.

What are your thoughts?

Regards

dc